OTCMKTS:IPHYF Innate Pharma (IPHYF) Stock Price, News & Analysis $1.65 0.00 (0.00%) As of 09/22/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartFinancialsNews and TrendsSEC FilingsShort Interest About Innate Pharma Stock (OTCMKTS:IPHYF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Innate Pharma alerts:Sign Up Key Stats Today's Range$1.65▼$1.6550-Day Range$1.65▼$1.6552-Week Range$1.37▼$2.25VolumeN/AAverage VolumeN/AMarket Capitalization$138.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Innate Pharma S.A. is a France-based biotechnology company focused on developing immunotherapies for cancer. The company’s research is centered on the innate immune system, including natural killer cells and other immune mechanisms that can recognize and attack tumor cells. Its activities include drug discovery, clinical development and collaborations with pharmaceutical companies. Innate Pharma’s pipeline has included antibody-based therapies designed to stimulate or direct immune responses against cancer. Its lead investigational programs have included lacutamab, an antibody being developed for certain T-cell lymphomas, and other oncology candidates targeting immune checkpoints and tumor-associated pathways. The company has also advanced programs through strategic partnerships, including collaborations with AstraZeneca involving monalizumab and other immuno-oncology assets. Founded in 1999 and headquartered in Marseille, France, Innate Pharma conducts research and development activities in Europe and works with international pharmaceutical partners to advance its therapies. The company’s leadership has included Chief Executive Officer Mondher Mahjoubi, who has guided its development as a clinical-stage immuno-oncology business. Innate Pharma’s shares trade in the United States under the symbol IPHYF.AI Generated. May Contain Errors. Read More Receive IPHYF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IPHYF Stock News HeadlinesSobi partnership with Innate Pharma takes effectSeptember 17, 2026 | marketscreener.comMInnate Pharma Secures Sobi Partnership Cash and Extends Runway as Key Oncology Trials AdvanceSeptember 17, 2026 | tipranks.comNASA's ISS Replacement Could Go to This Tiny Space FirmNASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to build its replacement is reportedly headed to a tiny firm a fraction of SpaceX's size, one NASA has quietly funded for five years. History shows these NASA announcements can move fast: Intuitive Machines jumped 66% in a day, Momentus soared 155%, and Sidus Space climbed 180% after landing subcontractor roles.September 24 at 1:00 AM | Behind the Markets (Ad)Innate Pharma to deliver H1 2026 business update via investor webcastSeptember 10, 2026 | tipranks.comInnate Pharma to Highlight Oncology Pipeline at H.C. Wainwright Investment ConferenceSeptember 2, 2026 | tipranks.comInnate Pharma to Spotlight Oncology Pipeline at H.C. Wainwright Investor ConferenceSeptember 2, 2026 | tipranks.comInnate Pharma Raises €30 Million in Private Share Placement to Fund Oncology PipelineAugust 19, 2026 | tipranks.comInnate Pharma SA Class A IPHYFAugust 19, 2026 | morningstar.comMSee More Headlines IPHYF Stock Analysis - Frequently Asked Questions How have IPHYF shares performed this year? Innate Pharma's stock was trading at $2.1550 on January 1st, 2026. Since then, IPHYF shares have decreased by 23.4% and is now trading at $1.65. How do I buy shares of Innate Pharma? Shares of IPHYF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today9/23/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:IPHYF Previous SymbolNASDAQ:IPHYF CIK1598599 Webwww.innate-pharma.com Phone(343) 030-3030Fax33-04-30-30-30-00Employees179Year Founded1999Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.27 Quick Ratio1.27 Sales & Book Value Annual Sales$10.19 million Price / Sales13.57 Cash FlowN/A Price / Cash FlowN/A Book Value($0.29) per share Price / Book-5.69Miscellaneous Outstanding Shares83,830,000Free Float57,097,000Market Cap$138.32 million OptionableNot Optionable Beta0.28 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (OTCMKTS:IPHYF) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredOn October 7th, your “safest” assets are at riskJeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...Brownstone Research | SponsoredWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...Trading Wire | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma SA Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
